Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Finance

Poland's Diagnostyka reports $17.5 million second quarter profit

Published by Global Banking and Finance Review

Posted on September 4, 2025

Featured image for article about Finance

GDANSK (Reuters) -Polish medical laboratory operator Diagnostyka, which listed on the stock exchange in February, reported a second-quarter net profit of 63.8 million zlotys ($17.53 million) on Thursday, driven by rising sales of tests and a higher average price per test.

The company continues its strategy of expanding through acquisitions, particularly in the field of diagnostic imaging. In July, Diagnostyka acquired NZOZ Pracownia Genetyki Nowotworów and a majority stake in VITA-SKAN.

"We are currently engaged in further acquisition discussions with several potential targets. While not every M&A negotiation leads to a deal, we expect to finalise more acquisitions in the medical imaging field this year," CEO Jakub Swadzba said in a statement.

Diagnostyka said its second-quarter operating revenue rose to 593.4 million zlotys from 591.6 million zlotys reported last quarter.

Its recurring EBITDA for the first half of the year came in at 314.1 million zlotys.

($1 = 3.6405 zlotys)

(Reporting by Julia Kotowska; Editing by Susan Fenton)